Table 2 Studies addressing the risk related to previous antibiotic therapy and emergence of carbapenem-resistant Enterobacteriaceae
From: Piperacillin–tazobactam as alternative to carbapenems for ICU patients
| Â | Year | Study design | Type of infection | Antibiotic concerned | OR, 95 % CI |
|---|---|---|---|---|---|
Wang [62] | 2016 | Retrospective case–case–control | Nosocomial infection | Third–fourth-generation cephalosporins Carbapenems | 4.557 (1.971–10.539) 4.058 (1.753–9.397) |
Mittal G [80] | 2016 | Prospective | Colonization | Aminoglycosides | 4.14 (1.14–14.99) |
Ling [81] | 2015 | Retrospective case–control | Infection or colonization | Penicillins Glycopeptides | 4.640 (1.529–14.079) 5.162 (1.377–19.346) |
Jiao Y [82] | 2015 | Retrospective case–control | Infection or colonization | Glycopeptides Cefoperazone plus sulbactam | 43.84 (1.73–1111.9) 49.56, (1.42–1726.72) |
Candevir [83] | 2015 | Retrospective cohort | Infection | Meropenem Third-generation cephalosporins | 3.244 (1.193–8.819) 3.590 (1.056–12.209) |
Gómez Rueda [84] | 2014 | Retrospective case–case–control | Infection | Carbapenems | 3.3 (1.2–9.3) |
Ahn [85] | 2014 | Retrospective case–control | Colonization/infection | Fluoroquinolones Carbapenems | 2.82 (1.14–6.99) 4.56 (1.44–14.46) |
Mantzarlis [86] | 2013 | Prospective cohort | Pneumonia | Colistin* | 1.156 per day (1.010–1.312) |
Dizbay [87] | 2013 | Prospective cohort | Nosocomial infection | Imipenem | 3.35 (1.675–6.726) |
Orsi [88] | 2013 | Retrospective case control | BSI | Carbapenem | 7.74 (1.70–35.2) |
Chang [89] | 2011 | Retrospective case–control | BSI | Carbapenem | 29.17 (1.76–484.70) |
Falagas [63] | 2007 | Retrospective case control | KPC infection | Fluoroquinolones Antipseudomonal antibiotics | 4.54 (1.18–11.54) 2.6 (1.00–6.71) |
Schwaber [61] | 2008 | Retrospective case–case–control | CRKp colonization | Antibiotics Fluoroquinolones | 4.4 (1–19.2) 7.2 (1.1–49.4) |
Gasink [60] | 2009 | Retrospective case–control | KPC infection/colonization | Fluoroquinolones Third-generation cephalosporin | 3.39 (1.5–7.66) 2.55 (1.18–5.22) |
Papadimitriou [64] | 2012 | Prospective cohort | CRKp colonization | BL/BLI Carbapenems | 6.7 (1–26.2) 5.2 (1–32.9) |
Tuon [90] | 2012 | Retrospective case–control | KPC bacteremia | Fluoroquinolones | 28.9 (1.85–454.6) |
Papadimitriou [91] | 2014 | Prospective cohort | KPC bacteremia | Aminoglycosides | 2.3 (1.1–4.7) |
Gagliotti [79] | 2014 | Case–control | KPC colonization | Carbapenems Any antibiotic (other than carbapenems) | 3.67 (1.37–9.83) 2.83 (1.10–7.31) |
Maseda [92] | 2016 | Retrospective | CPE isolate colonization | Third–fourth-generation cephalosporins BL/BLI | 27.96 (6.88–113.58) 11.71 (4.51–30.43) |